{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:27:45Z","timestamp":1780662465132,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MSD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10067-018-4324-7","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T03:42:00Z","timestamp":1539574920000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The persistence of golimumab compared to other tumour necrosis factor-\u03b1 inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs\u2014BioRx.si"],"prefix":"10.1007","volume":"38","author":[{"name":"on behalf of the Slovenian Rheumatologists","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-9189","authenticated-orcid":false,"given":"\u017diga","family":"Rotar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Tom\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Praprotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"4324_CR1","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, Van Der Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58:3402\u20133412. https:\/\/doi.org\/10.1002\/art.23969","journal-title":"Arthritis Rheum"},{"key":"4324_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU, GO-FORWARD Study (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68:789\u2013796. https:\/\/doi.org\/10.1136\/ard.2008.099010","journal-title":"Ann Rheum Dis"},{"key":"4324_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71:661\u2013667. https:\/\/doi.org\/10.1136\/ard.2011.154799","journal-title":"Ann Rheum Dis"},{"key":"4324_CR4","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Van Der Heijde D, McInnes IB et al (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64:2504\u20132517. https:\/\/doi.org\/10.1002\/art.34436","journal-title":"Arthritis Rheum"},{"key":"4324_CR5","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJB, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor \u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind. Arthritis Rheum 60:2272\u20132283. https:\/\/doi.org\/10.1002\/art.24638","journal-title":"Arthritis Rheum"},{"key":"4324_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J (2016) Five-year safety data from 5 clinical trials of subcutaneous Golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 43:2120\u20132130. https:\/\/doi.org\/10.3899\/jrheum.160420","journal-title":"J Rheumatol"},{"key":"4324_CR7","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.22860","volume":"68","author":"P Vashisht","year":"2016","unstructured":"Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K (2016) Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res 68:1478\u20131488. https:\/\/doi.org\/10.1002\/acr.22860","journal-title":"Arthritis Care Res"},{"key":"4324_CR8","doi-asserted-by":"crossref","unstructured":"Manara M, Caporali R, Favalli EG, et al (2017) Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol","DOI":"10.1136\/annrheumdis-2016-eular.5642"},{"key":"4324_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D\u2019Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47:108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Semin Arthritis Rheum"},{"key":"4324_CR10","doi-asserted-by":"publisher","unstructured":"Mourao AF, Ribeiro C, Borges J et al (2016) Real-life effectiveness of golimumab in biologic-naive rheumatoid arthritis patients-data from reuma.Pt, a portuguese registry. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.3653","DOI":"10.1136\/annrheumdis-2016-eular.3653"},{"key":"4324_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S (2016) Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int 36:987\u2013995. https:\/\/doi.org\/10.1007\/s00296-016-3423-5","journal-title":"Rheumatol Int"},{"key":"4324_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/03009742.2016.1234641","volume":"46","author":"K Aaltonen","year":"2016","unstructured":"Aaltonen K, Joensuu J, Piril\u00e4 L, Kauppi M, Uutela T, Varjolahti-Lehtinen T, Yli-Kerttula T, Isom\u00e4ki P, Nordstr\u00f6m D, Sokka T (2016) Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol 46:359\u2013363. https:\/\/doi.org\/10.1080\/03009742.2016.1234641","journal-title":"Scand J Rheumatol"},{"key":"4324_CR13","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, Equity in Clinical Eligibility Criteria for RA treatment Working Group (2014) Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth? Ann Rheum Dis 73:2010\u20132021. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203819","journal-title":"Ann Rheum Dis"},{"key":"4324_CR14","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10067-015-3066-z","volume":"34","author":"Z Rotar","year":"2015","unstructured":"Rotar Z, Ho\u010devar A, Rebolj Kodre A et al (2015) Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.Si registry. Clin Rheumatol 34:1787\u20131793. https:\/\/doi.org\/10.1007\/s10067-015-3066-z","journal-title":"Clin Rheumatol"},{"key":"4324_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"4324_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4324_CR17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"4324_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"4324_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/PPA.S128665","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A (2017) Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer Adherence 11:719\u2013729. https:\/\/doi.org\/10.2147\/PPA.S128665","journal-title":"Patient Prefer Adherence"},{"key":"4324_CR20","first-page":"159","volume":"4","author":"J Kay","year":"2010","unstructured":"Kay J, Rahman MU (2010) Golimumab: a novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 4:159\u2013170","journal-title":"Core Evid"},{"key":"4324_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semarthrit.2017.03.010","volume":"47","author":"GS Calip","year":"2017","unstructured":"Calip GS, Adimadhyam S, Xing S, Rincon JC, Lee WJ, Anguiano RH (2017) Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum 47:157\u2013164. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.010","journal-title":"Semin Arthritis Rheum"},{"key":"4324_CR22","unstructured":"R\u00e9my A, Avouac J, Gossec L Combe B clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29:96\u2013103"},{"key":"4324_CR23","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar3249","volume":"13","author":"R Rendas-Baum","year":"2011","unstructured":"Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors. Arthritis Res Ther 13:R25. https:\/\/doi.org\/10.1186\/ar3249","journal-title":"Arthritis Res Ther"},{"key":"4324_CR24","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, Van den Bosch F, Kron M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12:R117. https:\/\/doi.org\/10.1186\/ar3054","journal-title":"Arthritis Res Ther"},{"key":"4324_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS, Tarp U, Manilo N, Loft AGR, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72:1149\u20131155. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201933","journal-title":"Ann Rheum Dis"},{"key":"4324_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, Van Der Heijde D, Uhlig T et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70:157\u2013163. https:\/\/doi.org\/10.1136\/ard.2010.131797","journal-title":"Ann Rheum Dis"},{"key":"4324_CR27","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","volume":"35","author":"SM Reddy","year":"2016","unstructured":"Reddy SM, Crean S, Martin AL, Burns MD, Palmer JB (2016) Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 35:2955\u20132966. https:\/\/doi.org\/10.1007\/s10067-016-3425-4","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4324-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:58:07Z","timestamp":1775246287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4324"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4324-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ZR has received speaker fees from Abbvie, CellGen, Celtrion, Eli-Lilly, Jansen, Medis, MSD, Novartis, Pfizer and Roche. SP has received consultant or speaker fees from Abbvie, Eli-Lilly, Jansen, MSD, Novartis, Pfizer, Roche. MT has received consultant or speaker fees from Abbvie, Eli-Lilly, Johnson & Johnson, Medis, MSD, Novartis, Pfizer and Roche paid to Revmatic d.o.o. BioRx.si has received funding for clinical research paid to Dru\u0161tvo za razvoj revmatologije from AbbVie, Celgene, Celtrion, Eli Lilly, Johnson & Johnson, Medis, MSD, Novartis, Pfizer and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}